Testosterone in Menopause: What Atlanta Patients Can Ask After the FDA Workshop Notice

September 2, 2026Atlanta Medical Institute

After the FDA’s 2026 workshop notice, Atlanta patients can review evidence, uncertainties, and clinician-visit questions when discussing testosterone during menopause.

Why this topic now in Atlanta menopause care

Atlanta patients are hearing more about testosterone in menopause discussion after a 2026 FDA notice announcing a public meeting on testosterone use in menopausal women, scheduled for September 17, 2026, to examine evidence gaps and potential pathways for studying benefits and risks [7]. This moment is an opportunity to review what is known, what remains uncertain, and which questions to bring to a clinician visit for menopause care in Atlanta—especially if low sexual desire or related concerns are part of the conversation [7].

What the evidence currently supports

Current consensus statements and randomized trials suggest the clearest studied role for testosterone in postmenopausal women is for hypoactive sexual desire disorder (HSDD) after a careful biopsychosocial evaluation, with modest improvements in sexual desire and the number of satisfying sexual events compared with placebo in selected patients [4, 9, 10, 11]. Multiple trials, including a New England Journal of Medicine study of a transdermal preparation in postmenopausal women not taking estrogen, reported improvements in sexual desire and satisfying sexual activity versus placebo, while also noting increased rates of androgenic adverse effects such as acne or increased hair growth in some participants [10, 8]. A 2019 systematic review and meta-analysis found that transdermal testosterone, titrated to approximate physiologic premenopausal levels, improved sexual function domains in postmenopausal women with HSDD, with low-to-moderate effect sizes and an increased risk of mild androgenic side effects; long-term safety data remained limited [9, 12].

Where evidence is weak or insufficient

Consensus groups do not support using testosterone in women for indications outside sexual function, such as cognition, mood, musculoskeletal health, or general well-being, because evidence is insufficient or inconsistent [4, 2, 9]. The global consensus emphasizes that any consideration of testosterone should follow an assessment that addresses biological, psychological, and social contributors to low desire rather than focusing on a single hormone alone [4, 3].

Regulatory landscape: What the FDA workshop signals (not settles)

In 2026, the FDA announced a public meeting dedicated to testosterone use in menopausal women, highlighting the agency’s interest in evidence gaps, safety signals, outcome measures, and study pathways for potential future evaluations [7]. The meeting itself is intended to explore research and regulatory science questions rather than set immediate clinical policy, underscoring the need for high-quality data on benefits, risks, dosing targets, and monitoring—topics you can bring into a clinician-guided discussion in Atlanta [7].

Why testing and interpretation are complicated in women

Interpreting testosterone levels in women is technically challenging because concentrations are low and many routine immunoassays are less accurate in the female range; mass spectrometry–based methods are preferred when available for improved analytical performance [5, 1]. There is no universally accepted diagnostic cutoff that defines low testosterone in women, and symptoms alone are not specific to androgen status; this makes shared decision-making and careful interpretation essential when testosterone is part of the conversation [4, 3]. When labs are discussed, clinicians often consider how results align with premenopausal physiologic ranges and whether assay method, binding proteins such as SHBG, and comorbidities could be influencing measured values; patients can ask how these factors are handled in their evaluation [4, 5, 1].

Potential benefits and known risks to discuss

Across randomized trials, reported benefits have centered on improved sexual desire and increased satisfying sexual events in postmenopausal women with HSDD, with effect sizes that are typically modest at group level and variable between individuals [9, 10, 11]. Reported adverse effects are usually androgenic and dose-related, including acne and increased body or facial hair; higher exposures increase the likelihood of these events, and some androgenic effects can be distressing [9, 6]. Oral testosterone formulations have been associated with adverse lipid profile changes, which is one reason transdermal routes have been more commonly evaluated for women in research settings; however, long-term cardiovascular and breast safety remain uncertain due to limited duration of follow-up in trials [4, 9]. Meta-analyses and consensus statements emphasize that data beyond approximately one to two years are insufficient to determine long-term risks, including cardiovascular disease or breast cancer, underscoring the need for ongoing research and individualized risk–benefit discussions [4, 9, 2].

What remains uncertain—and why the workshop matters

Important uncertainties to surface in a visit include: the absence of long-term safety data; the lack of a validated diagnostic threshold for androgen deficiency in women; heterogeneity in trial populations and outcome measures; and variability in product formulations and assay accuracy that complicate comparisons across studies [4, 9, 5, 1]. The FDA’s 2026 meeting was convened to explore precisely these gaps—how to define clinically meaningful benefit, how to monitor exposure against physiologic female ranges, and how to evaluate safety over sufficient durations [7].

Questions to bring to an Atlanta menopause visit about testosterone

What symptom or quality-of-life changes are we trying to address, and how do we assess other contributors such as medications, pelvic pain, vaginal symptoms, sleep, mood, and relationship factors before focusing on testosterone? [3, 4]
Does my clinical picture meet criteria for hypoactive sexual desire disorder after a biopsychosocial evaluation, and how is that assessed? [3, 4]
If we discuss testosterone, what outcomes would we track (for example, sexual desire and satisfying sexual events), and over what time frame would we reassess? [9, 10]
How do you interpret testosterone levels in women at your practice, what assay method is used, and how do binding proteins such as SHBG factor into interpretation? [5, 1]
What potential adverse effects should I watch for, such as acne, increased hair growth, scalp hair thinning, or voice change, and what is the plan if these occur? Do not make any medication changes without speaking with the prescribing clinician [9, 4].
Are there differences in risk profiles between oral and transdermal approaches studied in women, and how do lipid changes influence the discussion? [9, 4]
How do we avoid exposures above physiologic premenopausal ranges, and how would monitoring help reduce the chance of androgenic adverse effects? [4, 6]
What are the major evidence gaps and uncertainties I should understand now, including limited long-term cardiovascular and breast safety data? [4, 9]
If I am not using estrogen therapy, does the evidence still apply, and what did studies in women not taking estrogen show? [8, 10]
What nonhormonal or behavioral approaches could be considered alongside or instead of hormone-focused options as part of a comprehensive plan? [3, 4]

Making sense of product types, lab variability, and marketing claims

Because there is no universally accepted diagnostic cutoff for low testosterone in women and no consensus on long-term safety, consensus guidance advises avoiding exposures that exceed physiologic premenopausal ranges and focusing on careful monitoring for androgenic effects if testosterone is considered after appropriate evaluation for HSDD [4]. Oral formulations have been associated with adverse changes in lipid profiles in trials, a point to discuss when reviewing options and personal risk factors [9]. Complicating matters, analytic variability across assays at low female concentrations can cloud interpretation, so patients can ask how the laboratory method and quality assurance are handled locally [5, 1]. Marketing language can sometimes overstate benefits for mood, energy, or general wellness; current evidence does not support broad claims beyond sexual function outcomes for selected patients after evaluation [4, 9, 2].

How the FDA workshop could shape future conversations—without changing today’s care overnight

FDA public workshops typically gather clinicians, researchers, patients, and industry to discuss evidence standards and unmet needs; the September 17, 2026 meeting is intended to explore study design, measurement, safety monitoring, and regulatory science questions specific to testosterone use in menopausal women [7]. Patients can ask clinicians how evolving guidance or future research might clarify appropriate candidates, clinically meaningful outcomes, and monitoring plans over time; for now, clinical decisions continue to rely on existing evidence, consensus statements, and individualized assessments [7, 4].

Atlanta context: Multidisciplinary considerations during menopause care

In a large, diverse metro area like Atlanta, menopause care often intersects with primary care, gynecology, mental health, sexual health, and cardiometabolic risk assessments—especially when conversations include sexual function, sleep, mood, and midlife health changes [3, 4]. A structured, clinician-guided plan that considers these dimensions helps keep the focus on goals that matter to you, even as the research evolves [4, 9].

Key takeaways for an evidence-based, Atlanta-focused discussion

Evidence is strongest for considering testosterone only in postmenopausal women with hypoactive sexual desire disorder after a careful biopsychosocial evaluation, with modest average benefits and individual variability [4, 9, 10].
Long-term cardiovascular and breast safety are not established; current trials are generally short to medium term, reinforcing the need to revisit risk–benefit considerations over time [4, 9, 2].
Assay accuracy at low female testosterone levels is a challenge; mass spectrometry methods are preferred when available, and results require context [5, 1].
Oral formulations have been linked to adverse lipid changes in women; this is a key discussion point when reviewing options and personal risk factors [9].
Avoiding supraphysiologic exposures and monitoring for androgenic adverse effects are central themes of consensus guidance if testosterone is considered [4, 6].
The FDA’s 2026 public meeting highlights ongoing evidence gaps and may inform future research standards, but it does not by itself change clinical care or product approvals [7].

FAQs: Testosterone in menopause discussion for Atlanta patients

What benefits has testosterone shown for postmenopausal women?

Evidence from randomized trials and meta-analyses suggests that testosterone can improve sexual desire and the number of satisfying sexual events in selected postmenopausal women diagnosed with hypoactive sexual desire disorder after evaluation, with modest average effect sizes and increased rates of mild androgenic side effects such as acne or hair growth [9, 10, 11].

Does testosterone help with energy, mood, bone, or brain health in menopause?

Consensus statements do not support testosterone for improving cognition, general mood, bone health, or overall vitality in women because evidence is insufficient or inconsistent; discussions should focus on sexual function outcomes when clinically appropriate [4, 2, 9].

Is a blood test enough to diagnose low testosterone in women?

There is no universally accepted diagnostic cutoff for low testosterone in women, assays can be inaccurate in the female range unless high-quality methods are used, and symptoms are nonspecific; clinicians often interpret results in the context of premenopausal physiologic ranges and the full clinical picture [4, 5, 1].

What side effects should be discussed before considering testosterone?

Reports of acne, increased body or facial hair, and scalp hair thinning occur more often with higher exposures; some trials also note voice changes or clitoral enlargement as less common concerns. Oral formulations have been associated with adverse lipid changes. Patients should discuss monitoring and not make medication changes without the prescribing clinician [9, 4, 6].

What does the 2026 FDA workshop mean for my options now?

The FDA scheduled a 2026 public meeting to examine testosterone use in menopausal women and related evidence gaps; this underscores active regulatory interest but does not by itself change current clinical practice or product availability [7].

A final word for Atlanta patients

Atlanta Medical Institute publishes health education to support clinician-guided menopause discussions grounded in current evidence and individualized goals. If testosterone comes up during your visit, use the questions in this article to guide a balanced, safety-conscious discussion that considers benefits, uncertainties, lab interpretation, and how monitoring would be approached in your specific situation. Do not make any medication changes without first speaking with your prescribing clinician [4, 3].

Sources

When to Talk With a Clinician

Contact Atlanta Medical Institute to discuss your goals, health history, and appropriate options with a qualified clinician.

Medical disclaimer: This article is for general education and is not a diagnosis or a substitute for individualized medical advice. Medication and hormone-treatment eligibility, risks, monitoring, and results vary; consult a qualified healthcare professional.